Drug
Ctx110
Ctx110: highest development phase Phase 1/2, developed by CRISPR Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- CRISPR Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CTX110 NCT04035434 | Phase 1/2 | B-cell Malignancy |
Latest
No recent events.
Follow Ctx110 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.